Maxime Dely: What if We Could Leukoreduce Without a Filter?
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared on LinkedIn:
”What if we could leukoreduce without a filter?
When we talk about leukoreduction, we immediately think of leukocyte filters — disposable devices able to remove over 99% of white blood cells.
But… not everyone has access to them.
In some countries, the cost of this technology remains a major barrier to transfusion safety.
Yet there’s a simple, effective, and affordable alternative: the hard spin.
In many developing countries, the first step in whole blood processing is a soft spin.
This yields two main components:
- a PRP (platelet-rich plasma),
- and an RCC (red cell concentrate).
The issue? Around 90% of the residual white blood cells end up in the RCC.
And these cells can cause febrile non-haemolytic transfusion reactions, allergic reactions, and can even impair red cell storage quality.
By performing a hard spin, we create an interface between plasma and red cells — the well-known buffy coat.
That’s where most white cells accumulate.
The result?
A significant reduction in the residual leukocytes within the red cell concentrate — sometimes divided by 2, from 90% to 50% or even lower, depending on the separation and centrifugation settings.
The hard spin isn’t a miracle solution, but it’s a crucial first step toward safer transfusion, especially where resources are limited.
Because sometimes, innovation simply means doing better with what we have.”
Stay updated with Hemostasis Today.
-
Dec 17, 2025, 15:24Laura Dormer on a Motor Relearning Program for Chronic Stroke Patients
-
Dec 17, 2025, 15:01WSO: United Nations Has Formally Adopted the Political Declaration on NCDs and Mental Health
-
Dec 17, 2025, 14:44Bryan Unger: 1st Patient Has Been Enrolled in NuvOx Therapeutics’ Phase IIb NOVEL Trial
-
Dec 17, 2025, 14:29Sarah Richardson: Feeling So Proud to Be a Part of the Advocacy Team for the HFA
-
Dec 17, 2025, 06:28Wolfgang Miesbach on Linus Völker’s Presentation of Caplacizumab as Frontline Therapy for iTTP
-
Dec 17, 2025, 06:11Lisa Murphy Thanks Stroke Foundation Team for An Impactful, Rewarding and Incredible Year
-
Dec 17, 2025, 06:05Emmanuel J Favaloro Shares A Study on AI and Machine Learning in Thrombosis and Hemostasis
-
Dec 17, 2025, 05:54Michael Bruckman: Fantastic to See Platelet-Inspired Nanoparticles Gaining Attention!
-
Dec 17, 2025, 04:00Peter Verhamme on Genetic Predisposition to Thromboembolism and COVID